Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Other Accumulated Expenses data on file, last reported at $308000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 30.16% year-over-year to $308000.0 in Q1 2026; TTM through Mar 2026 was $308000.0, a 30.16% decrease from a year earlier, with the FY2025 full-year figure at $258000.0, down 44.28% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $308000.0, up from $258000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for FULC reached as high as $463000.0 in Q4 2024 and fell as low as $9000.0 in Q1 2023.
• Historically, Other Accumulated Expenses has averaged $231117.6 across 5 years, with a median of $258000.0 in 2025.
• Across the five-year window, Other Accumulated Expenses tumbled 93.28% in 2023 and jumped 4177.78% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $105000.0 in 2022, then surged by 277.14% to $396000.0 in 2023, then grew by 16.92% to $463000.0 in 2024, then tumbled by 44.28% to $258000.0 in 2025, then grew by 19.38% to $308000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $308000.0 in Q1 2026, $258000.0 in Q4 2025, and $236000.0 in Q3 2025.